Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Amprenavir (Vertex Pharmaceuticals Inc).

A Billich1

  • 1Novartis Research Institute, Brunner Strasse 59, A-1235, Vienna, Austria. andreas.billich@pharma.novartis.com

Idrugs : the Investigational Drugs Journal
|September 13, 2005
PubMed
Summary

Amprenavir, a new HIV-protease inhibitor, shows potent antiviral activity and good oral absorption. Its favorable properties, including blood-brain barrier penetration, suggest efficacy in treating HIV and AIDS.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

GS-4104 Gilead Sciences Inc.

IDrugs : the investigational drugs journal·2008
Same author

Steroid sulfatase in the human hair follicle concentrates in the dermal papilla.

The Journal of investigative dermatology·2002
Same author

AIDSVAX. VaxGen.

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Entecavir (Bristol-Myers Squibb).

Current opinion in investigational drugs (London, England : 2000)·2001
Same author

Synthesis and biological evaluation of first N-alkyl syn dimeric 4-aryl-1,4-dihydropyridines as competitive HIV-1 protease inhibitors.

European journal of medicinal chemistry·2001
Same author

Sanglifehrin A, a novel cyclophilin-binding compound showing immunosuppressive activity with a new mechanism of action.

Journal of immunology (Baltimore, Md. : 1950)·2001

Area of Science:

  • Pharmacology
  • Virology
  • Drug Development

Background:

  • Amprenavir is an oral, non-peptidic HIV-protease inhibitor.
  • It is currently in phase III clinical trials for HIV and AIDS treatment.

Purpose of the Study:

  • To evaluate the efficacy and pharmacokinetic profile of amprenavir.
  • To assess its potential as a novel therapeutic agent for HIV/AIDS.

Main Methods:

  • Clinical trials (Phase III) for efficacy and safety.
  • Pharmacokinetic studies including absorption, half-life, and bioavailability.
  • In vitro studies on HIV-1 protease inhibition and genotypic resistance.

Main Results:

  • Amprenavir demonstrates potent and specific inhibition of HIV-1 protease and replication in T-cells.
  • Good oral absorption with a plasma half-life of approximately 10 hours, allowing twice-daily dosing.
  • Apparent penetration of the blood-brain barrier and unique resistance profile with limited cross-resistance to other protease inhibitors.

Conclusions:

  • Amprenavir possesses favorable pharmacokinetic properties and potent antiviral activity.
  • Its characteristics suggest potential as an effective oral treatment for HIV/AIDS, including potential long-term benefits due to blood-brain barrier penetration.

Related Experiment Videos